Alcon brings Balance eye drops to Latin America
This article was originally published in The Tan Sheet
Executive SummaryBy the end of 2010, Alcon plans to distribute in Latin America Systane Balance Lubricant Eye Drops for consumers who have dysfunctional meibomian glands, a condition commonly linked to dry eye syndrome. The Swiss firm said Oct. 11 Systane Balance contains hydroxypropyl-guar - derived from the Guar galactomannan water-soluble polysaccharide - borate, sorbitol, propylene glycol and Alcon's LipiTech System, an emulsion technology of mineral oil and an anionic phospholipid. Alcon designed the product to restore the lipid layer and the natural tear film to allow for relief of dry eye symptoms. Tear film instability can occur when meibomian glands in eyelids do not secrete adequate amounts of lipid to seal the aqueous tears and prevent evaporation. Alcon launched the product in the U.S. in July. A 10-mL bottle of Systane Balance is available online for $12.99 and a two-bottle pack for $19.99
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.